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Some neuronal-derived CD4-negative cells are susceptible to infection with human immunodeficiency virus type 1 (HIV-
1). Galactosyl ceramide is an alternate receptor for HIV-1 that appears to bind in vitro to the C2, V3, V4, and V5 regions of
gp120. Amino acid variation in the V3 loop of HIV-1 affects cellular tropism in CD4-positive cells, but its effect on CD4-
negative cells has not been fully analyzed. Here, we describe the effect of amino acid changes in V3 on the HIV-1 infection
of a CD4-negative neuronal cell line, SK-N-MC. The sequence of the V3 domain was found to dramatically alter virus
infectivity. Furthermore, a gp120 V3 loop neutralizing monoclonal antibody blocked HIV-1 infection on SK-N-MC cells. This
data suggests that V3 may also serve as a primary viral determinant for infectivity of CD4-negative cells. q 1996 Academic
Press, Inc.
Infection of T helper lymphocytes by human immuno- infection on these cells (26). It appears that the interac-
deficiency virus type 1 (HIV-1) requires the presence of tion between GalCer and gp120 involved multiple sites
the CD4 surface molecule, which serves as the virus on the envelope protein.
receptor (1, 2). The specific domains on both gp120 and The V3 loop of gp120 has been identified as a primary
CD4 that are involved in this high-affinity envelope–re- determinant of HIV-1 cell tropism (27–29). Specific se-
ceptor interaction have been well defined (3–7). How- quences within the V3 loop have been associated with
ever, HIV-1 infects some cells that do not express CD4, either the macrophage-tropic or the T-cell-tropic pheno-
including selected brain-derived glial, neuronal, and reti- type (27, 30–34). While residues in the V3 loop are known
nal cells, brain capillary endothelial cells, human skin to affect cellular tropism in CD4-positive cells, little is
fibroblast, muscle and bone-derived fibroblastoid cell known about the effect of V3 sequences in CD4-negative
lines, human trophoblast cells, follicular dendritic cells, cells. Here using a HIV-1IIIb derivative molecular clone,
fetal adrenal cells, and human liver carcinoma cells (8– HxB2RU3, we investigate the role of the gp120 V3 loop
19). One such CD4-negative cell line that can be produc- in HIV-1 infection of a CD4-negative SK-N-MC cell line.
tively infected with HIV-1 is the neuronal cell line SK-N- The results indicate that the V3 loop serves as a primary
MC (19). Studies with SK-N-MC or a glial cell CD4- viral determinant for infectivity in CD4-negative SK-N-MC
negative cell line, U373-MG, have identified galactosyl cells.
ceramide (GalCer) as a potential receptor of HIV-1 using Tumor cell line SK-N-MC of neuronal origin was ob-
rabbit polyclonal antibodies to GalCer (20, 21). A similar tained from the American Type Culture collection (Rock-
observation was made in an epithelial cell line from the ville, MD). SupT1 was obtained from the AIDS Research
colon, HT29 (22). Using high-performance thin-layer chro- and References Reagent Program, National Institutes of
matography binding assays, GalCer has been shown to Health (Bethesda, MD). SK-N-MC and SupT1 were main-
bind to residues in the region C2 and the V3 loop of HIV- tained at 377 in RPMI 1640 medium containing 10% heat-
1 gp120 (23, 24). In addition, synthetic V3 peptides were inactivated fetal bovine serum and 1% antibiotic. Each
shown to bind to GalCer and to block HIV-1 infection cell line was inoculated with a stock of the HTLV-IIIb
in HT29 cells (25). Recently, using chimeras obtained isolate (HIV-1IIIb), which was obtained from the AIDS Re-
between viruses that infect (HIV-1HxB2) or do not infect search and References Reagent Program, National Insti-
(HIV-189.6) SK-N-MC cells, the V3, V4, and V5 regions of tutes of Health (Bethesda, MD). For the HIV-1IIIb , the infec-
gp120 have been identified as critical to confer positive tious dose was based on quantification of virus by a 50%
tissue culture infective dose (TCID50) assay as previously
indicated (35). A TCID50 of 500 was used to infect both1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (617) 739-8348. 5 1 106 SK-N-MC and SupT1 cells. Cells were exposed
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FIG. 1. HIV-1 infection of SK-N-MC and SupT1 cells. (A) Kinetics of HIV-1IIIb and its molecular clone HxB2RU3 in the SK-N-MC CD4-negative cell
line. (h) SK-N-MC / HIV-1IIIb ; (L) SK-N-MC / HIV-1HxB2RU3 ; (s) SK-N-MC / Mock. (B) Kinetics of HIV-1IIIb and its molecular clone HxB2RU3 in the
SupT1 CD4-positive cell line. (h) SupT1 / HIV-1IIIb; (L) SupT1 / HIV-1HxB2RU3 ; (s) SupT1 / Mock. Virus replication was monitored by the production
of released p24 on Days 6, 12, 18, and 24 postinfection.
to the virus for 16 hr at 377, washed five times with phos- type HIV-1IIIb despite similar infectious doses. One possi-
ble explanation for these findings is that the additionalphate-buffered saline (GIBCO/BRL), and resuspended in
fresh, complete media. The cultures were then monitored viruses derived from HIV-1IIIb may be involved in the infec-
tivity. However, the HxB2RU3 infection of SK-N-MC cellsevery 6 days for 24 days for core antigen (p24) production
in the supernatant fluid by the antigen-capture method may provide a good system for identification of the gp120
determinant. In contrast, as shown in Fig. 1B, both the(Abbott Laboratories, North Chicago, IL). During the
course of the experiment, infection by the HIV-1IIIb strain HIV-1IIIb and its molecular clone reacted similarly in a
positive control SupT1 cell line. The kinetics of infectivitywas observed in the SK-N-MC cell line after 12 days
postinfection (data not shown). These findings are in of HIV-1IIIb and its molecular clone were reproduced in
four separate experiments.agreement with previous studies (19). As a positive con-
trol, a T cell line, SupT1, was used to determine the Harouse et al. (26), using the HIV-1HxB2 molecular
clone, had shown that a 580-bp fragment of the env genesusceptibility to HIV-1IIIb infection. We repeated the same
experiments using 250 and 500 TCID50 , which yielded flanked by conserved BlgII sites translates into a 193-
amino-acid fragment that encompasses the V3, V4, andsimilar results.
The HIV-1IIIb was derived from concentrated culture V5 domains of gp120, which is important for HIV-1 infec-
tion on SK-N-MC cells. Furthermore, they observed iden-fluids of peripheral blood or bone marrow from several
patients with AIDS or related diseases (36, 37). In order tical results when they divided the 580-bp region into
two domains: the 91-amino-acid envelope fragment ofto study the molecular determinant of gp120 of HIV-1IIIB
that confers the SK-N-MC infectivity, we first analyzed the HxB2 containing the V3 and the 101-amino-acid enve-
lope fragment of the HxB2 containing V4 and V5. Mean-the kinetics of infection of its derived molecular clone
HxB2RU3 on SK-N-MC cells. The HIV-1 proviral clone while, residues in the V3 loop have been identified as
the main determinant in HIV-1 cell tropism (27–34). WeHxB2RU3 is a derivative of HIV-1IIIb (38) with full-length
vpu, vpr, and nef genes. The infectious molecular clone set out to determine whether changes in amino acid
residues of the V3 loop of HxB2RU3 result in changesHxB2RU3 was introduced into Cos-7 cells as previously
described by DEAE-Dextran-mediated transfection (39). of virus infectivity. Using site mutagenesis as described
previously (40), a mutant proviral clone, HxB2RU3CI,Cos-7 cells, which constituitively express simian virus 40
large T antigen, were obtained from the American Type which contained the consensus V3 sequence on the
background of HxB2RU3, was constructed (Fig. 2). TheCulture collection (Rockville, MD). Cos-7 cells were main-
tained in Dulbecco’s modified Eagle’s medium (DMEM) consensus sequence was identical to the V3 sequence
of macrophage-tropic viruses. Preparation of the viralsupplemented with 10% heat-inactivated fetal bovine se-
rum and antibiotics (DMEM complete medium). For the stock of the molecular clone HxB2RU3CI and its infection
on SK-N-MC were performed as mentioned above. Inter-infection study, the TCID50 of HxB2RU3 was measured
as previously described. Using similar infectious stock estingly, infectivity of SK-N-MC cells by this chimeric
HxB2RU3CI virus gave a negative result (see Fig. 3A). Tothe HIV-1IIIb and HxB2RU3 viruses were used to infect
SK-N-MC and SupT1 cells. As shown in Fig. 1A, both the exclude the possibility that the V3 sequence change in
the gp120 of this chimeric virus may have altered itsHIV-1IIIb and its derived molecular clone HxB2RU3 infect
the neuronal CD4-negative cell line. The kinetics of infec- infectivity for lymphocytes, a positive cell control, the
SupT1 cells, was tested. SupT1 cells showed a produc-tivity of HxB2RU3 were lower when compared to the wild-
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HIV-1 infection in SK-N-MC cells (19). Using 30 mg of the
OKT4A did not prevent HxB2RU3 infection in SK-N-MC
cells (see Table 1). Bovine albumin (30 mg) was used as
an internal control and it did not show any inhibition
effect. This blocking experiment was repeated twice with
similar results. Taken together, the above results indicate
that the V3 loop is an important determinant of gp120 for
entry of HIV-1 in neuronal SK-N-MC CD4-negative cells.
In this study we have shown that the susceptibility of
a neuronal CD4-negative cell line to infection by HIV-1IIIb
and its molecular clones depends on the specific V3
loop. SK-N-MC was infected by the HIV-1IIIb strain and
its molecular clone, HxB2RU3, both of which have V3FIG. 2. A schematic representation of the sequence alignment of
positive charged sequences. This finding was confirmedcysteine296 to cysteine331 of the V3 loop of HIV-1 gp120. The entire
chimeric virus HxB2RU3CI has the gp120 HxB2RU3 sequence except when a molecular clone derived from HIV-1IIIb, HxB2R3CI,
for the V3 region that corresponds to the consensus sequence. inhibited the infection on SK-N-MC after its V3 positive
loop was substituted for a consensus sequence V3 loop.
In addition, the V3 pathway entry into the CD4-negativetive infection by HxB2RU3CI (see Fig. 3B). The lack of viral
cells was also confirmed by blocking infection with aproduction on SK-N-MC by HxB2RU3CI was repeated in
neutralizing V3 loop monoclonal antibody.five experiments each yielding identical results.
Galactosyl ceramide has been shown as an alternativeTo confirm whether the HIV-1 infection on SK-N-MC
receptor for HIV-1 that binds to the C2 V3, V4, and V5cells is via the V3 loop pathway, blocking infection was
regions of HIV-1 gp120 (23, 24, 26). One study (23) re-performed using an HIV-1 gp120 V3 loop neutralizing
ported that amino acids 206 to 275, corresponding to themonoclonal antibody (mAb) (NEA-9205, Boston, MA) (41).
C2 region of gp120, bind to GalCer. Another study (24),Five dilutions of V3 mAb (1:50, 1:200, 1:800, 1:3200,
using a panel of HIV-1 monoclonal antibodies, deter-1:12,800) were incubated with using 250 TCID50 of
mined that the V3 loop interacts with the GalCer receptor.HxB2RU3 for 1 hr at 377. Infection was performed as
A recent study (25) confirms this finding using anothermentioned above, and viral replication was monitored by
cell system, colon (HT29) epithelial cells which expressthe release of p24 on Days 6, 12, 18, and 24 postinfection.
GalCer. They showed evidence that the V3 loop is in-Table 1 shows the results on Day 24, where dilutions
volved in the binding of gp120 and the GalCer receptor.1:50, 1:200, and 1:800 of the V3 mAb HIV-1 completely
Recently (26), using chimeric viruses that infect or do notblocked infection in SK-N-MC cells. Higher dilutions,
infect SK-N-MC cells, the V3, V4, and V5 of gp120 were1:3200 and 1:12,800, did not block HIV-1 infection. As
identified as critical for viral entry into the SK-N-MC cellexpected, without any V3 mAb, HIV-1 infection on SK-N-
line. The above findings indicate that tropism for thisMC was obtained. As previously described, a monoclonal
cell line is dependent on a complex interaction involvingantibody, OKT4A (Ortho Diagnostics), directed against the
gp120-binding site on the CD4 molecule did not block multiple regions of the gp120. Our genetic approach,
FIG. 3. Infection of SK-N-MC and SupT1 cells by HIV-1 molecular clones. (A) Kinetics of HIV-1 molecular clones HxB2RU3 and HxB2RU3CI viral
replication in the SK-N-MC CD4-negative cell line. (h) SK-N-MC / HxB2RU3; (L) SK-N-MC / HxB2RU3CI; (s) SK-N-MC / Mock. (B) Kinetics of
HIV-1 molecular clones HxB2RU3 and HxB2RU3CI viral replication in the SupT1 CD4-positive cell line. (h) SupT1 / HxB2RU3; (L) SupT1 /
HxB2RU3CI; (s) SupT1 / Mock. Viral replication was monitored by the production of secreted p24 on Days 6, 12, 18, and 24 postinfection.
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TABLE 1 1IIIb and HIV-1JRFL , respectively, were reproduced in four
similar experiments. Whether the positive sequence ofBlocking Experiment Using Anti-HIV-1 gp120 V3
the V3 loop domain of gp120 is the main determinant forLoop Neutralizing Antibody
tropism of all CD4-negative cells or GalCer is the only
SK-N-MC infection receptor of all CD4-negative cells needs to be investi-
Antibodies (p24 pg/ml) gated. This information has important implications for
blocking strategies of HIV-1 infection in CD4-negativeV3 mAb dilutionsa
entry.1:50 £1
1:200 £1 Our findings may also have implications in the neuro-
1:800 £1 pathogenesis of HIV-1 infection. Obviously, our in vitro
1:3200 100 findings with tumor neuronal SK-N-MC cell line cannot
1:12,800 100
be extrapolated to in vivo situations with normal neurons.No antibody 100
Nevertheless, if neurons are indeed infected, then theOKT4A (30 mg/ml) 100
Bovine albumin (30 mg/ml) 100 positive V3 loop may play a key role for neuronal HIV-1
tropism. Alternately, if they are not infected but gp120
a Five dilutions of V3 mAb were incubated using 250 TCID50 of HIV- binds to GalCer throughout the V3 loop, this binding may
1 molecular clone HxB2RU3 for 1 hr at 377. CD4 mAb (OKT4A) and
cause some pathology such as increasing intracellularbovine albumin were used as internal controls and they did not show
calcium leading to neuronal cell death as has been sug-inhibitory effect. Virus replication was monitored by the production of
released p24 on Days 6, 12, 18, and 24 postinfection. Data shown were gested (43). In addition to neurons, other cells such as
derived from two independent experiments at Day 24 postinfection. glial cells can be infected both in vivo and in vitro (10,
44–46). Glial cells have been shown to express GalCer
on their surface (21). So far, most of the viruses isolated
using HIV-1 molecular clones, shows that a V3 loop from the brains of HIV-1-infected individuals have been
serves as a primary viral determinant for infectivity in this linked to a macrophage genotype (47–49). In addition,
SK-N-MC CD4-negative cell. Our results are consistent one study in vitro had shown that the same V3 sequence
with previous experiments which demonstrate inhibition that confers tropism to macrophages converts the virus
of gp120–GalCer binding by V3 loop antibodies (24). In to infect microglial cells (50). However, these data are
addition, several V3 loop peptides can bind to GalCer derived from brains with HIV-1 encephalitis which in turn
and block infection of a CD4-negative epithelial colon has been associated with the infection of macrophages/
cell line, HT29 (25). microglial cells. It is unknown whether positive specific
These observations have several implications. First, sequences in the V3 loop of HIV-1 are responsible for
several studies have demonstrated that specific se- the infection of neuronal or glial cells from patients with
quences within the V3 loop have been associated with AIDS encephalopathy. Therefore, future characterization
either the macrophage-tropic or the T-cell-tropic pheno- of HIV-1 derived from these cells is warranted.
type (30–34). T-cell-line-tropic viruses tend to have more
positively charged residues, particularly in certain posi-
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